Kyverna Therapeutics (NASDAQ:KYTX) Stock Rating Lowered by Wall Street Zen

Kyverna Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded Kyverna Therapeutics from “sell” to “strong sell,” while analyst opinions remain mixed: MarketBeat reports an overall “Moderate Buy” consensus and a $29 average price target.
  • Kyverna shares opened at $4.26, near their 52-week low of $4.18, and below their 50-day ($5.90) and 200-day ($7.79) moving averages.
  • The clinical-stage biotech reported a quarterly loss of $0.68 per share, slightly better than analysts’ $0.69 loss estimate.
  • Five stocks we like better than Kyverna Therapeutics.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) was downgraded by analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a report issued on Saturday, Wall Street Zen reports.

A number of other brokerages also recently commented on KYTX. William Blair upgraded Kyverna Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 23rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kyverna Therapeutics in a research report on Monday, September 21st. Benchmark reiterated a "buy" rating on shares of Kyverna Therapeutics in a research report on Friday, September 25th. Needham & Company LLC set a $25.00 price target on Kyverna Therapeutics in a report on Friday, September 25th. Finally, HC Wainwright restated a "buy" rating on shares of Kyverna Therapeutics in a research report on Thursday, October 22nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $29.00.

View Our Latest Analysis on Kyverna Therapeutics

Kyverna Therapeutics Stock Down 2.5%

Shares of NASDAQ:KYTX opened at $4.26 on Friday. The business's 50-day moving average is $5.90 and its 200 day moving average is $7.79. Kyverna Therapeutics has a 1 year low of $4.18 and a 1 year high of $13.67. The company has a quick ratio of 7.01, a current ratio of 7.01 and a debt-to-equity ratio of 0.19.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.01. On average, analysts anticipate that Kyverna Therapeutics will post -2.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kyverna Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Legal & General Group Plc purchased a new stake in Kyverna Therapeutics during the second quarter worth approximately $36,000. North Star Investment Management Corp. acquired a new position in Kyverna Therapeutics in the third quarter valued at approximately $68,000. Kovack Advisors Inc. acquired a new position in Kyverna Therapeutics in the third quarter valued at approximately $65,000. State of Wyoming purchased a new position in Kyverna Therapeutics in the second quarter valued at approximately $97,000. Finally, Allianz Asset Management GmbH purchased a new position in Kyverna Therapeutics in the second quarter valued at approximately $98,000. 18.08% of the stock is owned by hedge funds and other institutional investors.

Kyverna Therapeutics Company Profile

(Get Free Report)

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for people with autoimmune diseases. The company's approach aims to use engineered immune cells to address disease-causing B cells. Its lead candidate, KYV-101, is an autologous CAR T-cell therapy designed to target CD19, a protein found on B cells. Kyverna is evaluating the therapy in clinical studies for several autoimmune conditions, including stiff person syndrome, myasthenia gravis and lupus nephritis.

Recommended Stories

Analyst Recommendations for Kyverna Therapeutics (NASDAQ:KYTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Kyverna Therapeutics Right Now?

Before you consider Kyverna Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kyverna Therapeutics wasn't on the list.

While Kyverna Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines